Post-transplant cyclophosphamide pharmacokinetics and haploidentical hematopoietic cell transplantation outcomes: an exploratory study

Abstract Pharmacokinetics of cyclophosphamide has been explored to optimize conditioning dosing. We hypothesized that post-transplant cyclophosphamide (PTCy) metabolite carboxy-ethyl phosphoramide mustard (CEPM) pharmacokinetics might impact haploidentical transplantation (haplo-HCT) outcomes. CEPM area under the curve (AUC0–48) was determined by eleven sampling timepoints on day +3/+4 using LC-MS/MS. The median CEPM AUC0–48 in a cohort of 30 patients was 14.2 (14) mg·hr/L. The incidence of severe chronic graft-versus-host disease (GVHD) (73% vs. 11%, p = 0.02), and GVHD-/relapse-free survival (GRFS) was significantly inferior in the CEPM AUC0–48 < 14 mg·hr/L group (54 days vs. 344 days, p = 0.02). There was, however, no difference in grade III-IV acute GVHD (38% vs. 14%, p = 0.12) and overall survival (295 days vs. not reached, p = 0.2). CEPM AUC0–48, is associated with severe chronic GVHD and GRFS post-haplo-HCT in this exploratory study. There is scope for personalizing day + 4 PTCy dose based on day + 3 CEPM AUC0–8.

[1]  D. Lad,et al.  Cyclophosphamide, hydroxycyclophosphamide and carboxyethyl phosphoramide mustard quantification with liquid chromatography mass spectrometry in a single run human plasma samples: A rapid and sensitive method development. , 2022, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[2]  Thomas E. Hughes,et al.  Phase I/II Study of Reduced Dosing of Post-Transplantation Cyclophosphamide (PTCy) after HLA-Haploidentical Bone Marrow Transplantation , 2021, Blood.

[3]  Shannon R. McCurdy,et al.  Signatures of GVHD and Relapse after Post-Transplant Cyclophosphamide Revealed by Immune Profiling and Machine Learning. , 2021, Blood.

[4]  Catherine J. Wu,et al.  Impaired T- and NK-cell reconstitution after haploidentical HCT with posttransplant cyclophosphamide. , 2021, Blood advances.

[5]  R. Vij,et al.  Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[6]  D. Venzon,et al.  Optimized Timing of Post-Transplantation Cyclophosphamide in MHC-Haploidentical Murine Hematopoietic Cell Transplantation: Optimized timing of PTCy in haploidentical HCT. , 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[7]  D. Venzon,et al.  Post-transplantation cyclophosphamide prevents graft-versus-host disease by inducing alloreactive T cell dysfunction and suppression. , 2019, The Journal of clinical investigation.

[8]  Lara E Sucheston-Campbell,et al.  Replication and validation of genetic polymorphisms associated with survival after allogeneic blood or marrow transplant. , 2017, Blood.

[9]  M. Labopin,et al.  Definition of GvHD-free, relapse-free survival for registry-based studies: an ALWP–EBMT analysis on patients with AML in remission , 2016, Bone Marrow Transplantation.

[10]  L. Luznik,et al.  Modern approaches to HLA-haploidentical blood or marrow transplantation. , 2016, Nature Reviews Clinical Oncology.

[11]  D. Porter,et al.  International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International Consortium. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[12]  Daniel Wolff,et al.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[13]  J. McCune,et al.  Pharmacokinetics, Pharmacodynamics and Pharmacogenomics of Immunosuppressants in Allogeneic Haematopoietic Cell Transplantation: Part I , 2015, Clinical Pharmacokinetics.

[14]  Marianna Zahurak,et al.  Aldehyde Dehydrogenase Expression Drives Human Regulatory T Cell Resistance to Posttransplantation Cyclophosphamide , 2013, Science Translational Medicine.

[15]  M. Sorror,et al.  A pilot pharmacologic biomarker study in HLA-haploidentical hematopoietic cell transplant recipients , 2013, Cancer Chemotherapy and Pharmacology.

[16]  B. Andersson,et al.  Role of pharmacogenetics in busulfan/cyclophosphamide conditioning therapy prior to hematopoietic stem cell transplantation. , 2013, Pharmacogenomics.

[17]  D. Salinger,et al.  Personalized Dosing of Cyclophosphamide in the Total Body Irradiation–Cyclophosphamide Conditioning Regimen: A Phase II Trial in Patients With Hematologic Malignancy , 2009, Clinical pharmacology and therapeutics.

[18]  R. Porcher,et al.  Association of drug metabolism gene polymorphisms with toxicities, graft-versus-host disease and survival after HLA-identical sibling hematopoietic stem cell transplantation for patients with leukemia , 2009, Leukemia.

[19]  S. Rodenhuis,et al.  Relations between polymorphisms in drug-metabolising enzymes and toxicity of chemotherapy with cyclophosphamide, thiotepa and carboplatin , 2008, Pharmacogenetics and genomics.

[20]  Jos H Beijnen,et al.  Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide , 2008, Pharmacogenetics and genomics.

[21]  S. Rodenhuis,et al.  Simultaneous quantification of cyclophosphamide and its active metabolite 4-hydroxycyclophosphamide in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry (LC-MS/MS). , 2007, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[22]  Brian R. Phillips,et al.  Real-time Dose Adjustment of Cyclophosphamide in a Preparative Regimen for Hematopoietic Cell Transplant: A Bayesian Pharmacokinetic Approach , 2006, Clinical Cancer Research.

[23]  Brian R. Phillips,et al.  Rapid quantitation of cyclophosphamide metabolites in plasma by liquid chromatography-mass spectrometry. , 2006, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[24]  Brian R. Phillips,et al.  Metabolism‐based cyclophosphamide dosing for hematopoietic cell transplant , 2005, Clinical pharmacology and therapeutics.

[25]  H. Leather.  Drug interactions in the hematopoietic stem cell transplant (HSCT) recipient: what every transplanter needs to know , 2004, Bone Marrow Transplantation.

[26]  T. Gooley,et al.  Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation. , 2003, Blood.

[27]  F. Appelbaum,et al.  Pharmacokinetics of cyclophosphamide and its metabolites in bone marrow transplantation patients , 1998, Clinical pharmacology and therapeutics.